Canada’s Sunnybrook Health Sciences Centre Joins Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy

  Canada’s Sunnybrook Health Sciences Centre Joins Elekta and Philips Research
  Consortium on MRI-Guided Radiation Therapy

Research projects to have implications for cancer treatment worldwide

Business Wire

STOCKHOLM, Sweden -- May 10, 2013

Regulatory News:

Elekta (NSE: EKTAb) and Royal Philips Electronics (NYSE: PHG, AEX: PHIA)
announced today that Sunnybrook Health Sciences Centre (Toronto, Canada) will
join their growing consortium to validate the clinical potential of MRI-guided
radiation therapy.

Sunnybrook Health Sciences Centre, the sixth largest cancer center in North
America, is the fourth member to sign the research agreement to evaluate the
new technology, which merges radiation therapy and magnetic resonance imaging
(MRI) in a single system. Current clinical members of the group include the
University Medical Center Utrecht, The University of Texas MD Anderson Cancer
Center, and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital.

Integrating an advanced 1.5 Tesla MRI machine with a sophisticated radiation
therapy system will provide physicians with exceptional depictions of a
patient’s soft tissues and tumor and allow them to dynamically track their
motion. This breakthrough innovation is designed to permit doctors to deliver
radiation in real time under MR guidance for the most precise cancer
treatments possible.

“Sunnybrook Health Sciences Centre distinguishes itself in the world of
science and medicine by its longstanding dedication of integrating research
into clinical domain for the benefit of patients,” says Tomas Puusepp, Elekta
President and CEO. “With their international strength in the physical sciences
– particularly in imaging technology – and its worldwide repute as a top
flight cancer center, Sunnybrook is an ideal partner to help us advance this
new technology.”

According to Michael Julius, Vice President, Research at Sunnybrook Health
Sciences Centre, Sunnybrook’s participation in the research consortium will
bring a unique team of physicists, engineers and clinicians to focus on
validating the advantages of MRI-guided radiation therapy through technology
development and clinical trials.

“We have identified a number of areas to study the value of this technology
for patients,” he says. “The ultimate goal – acquiring high resolution MRI
images of pathology in real time as the radiation is being delivered – could
have a dramatic impact on patient health and clinical outcomes.”

Today, the safety margin of normal tissue around the tumor absorbs a large
portion of the radiation beam, adds Jean-Philippe Pignol, Professor of
Radiation Oncology and a key leader on the Elekta partnership at Sunnybrook’s
Odette Cancer Centre. “The expectation is that MR-guided radiation therapy
will enable us to treat more cancer tissue than normal tissue. In doing so, we
could apply, in a single fraction, a huge dose to the tumor while avoiding
side effects to normal tissues,” he says.

“The development of advanced imaging solutions for oncology therapy planning
and delivery is a key focus area for Philips,” says Gene Saragnese, CEO
Imaging Systems at Philips Healthcare. “Philips is already closely working
together with Sunnybrook Health Sciences Centre in this field, and we welcome
their expertise to the research consortium for MR guided radiotherapy. The
members will jointly work on the design and implementation of the clinical
studies with the objective of bringing image-guided oncology therapy to the
next level, and ultimately creating the future of healthcare.”

The integrated MRI-guided radiation therapy system is in development and not
available for sale.

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on May 10, 2013.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow
enhancing software systems across the spectrum of cancer care. Stretching the
boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare
providers and patients, Elekta aims to improve, prolong and even save patient
lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,400 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

About Royal Philips Electronics

Royal Philips Electronics (NYSE: PHG, AEX: PHIA) is a diversified health and
well-being company, focused on improving people’s lives through meaningful
innovation in the areas of Healthcare, Consumer Lifestyle and Lighting.
Headquartered in the Netherlands, Philips posted 2012 sales of EUR 24.8
billion and employs approximately 116,000 employees with sales and services in
more than 100 countries. The company is a leader in cardiac care, acute care
and home healthcare, energy efficient lighting solutions and new lighting
applications, as well as male shaving and grooming and oral healthcare. News
from Philips is located at www.philips.com/newscenter.

This information was brought to you by Cision http://news.cision.com

Contact:

Elekta AB
Johan Andersson, Director, Investor Relations
Tel: +46 702 100 451
email: johan.andersson@elekta.com
Time zone: CET: Central European Time
or
Elekta
Michelle Joiner, Director, Global Public Relations and Brand Management
Tel: +1 770-670-2447
email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time
or
Philips Corporate Communications
Steve Klink, +31 20 5977415
steve.klink@philips.com
 
Press spacebar to pause and continue. Press esc to stop.